Pipeline
F3PB’s pipeline includes a range of innovative cytoprotection and radioprotection technologies aimed at minimizing the harmful effects of radiation exposure.
Product Pipeline
| PROGRAM | RATIONALE | PRE-CLINICAL | PHASE 1 | PHASE 2 | PHASE 3 | REGISTRATION |
|---|---|---|---|---|---|---|
| Amiguard CT RIGDI | Initial indication - $14B opportunity (IV access only) | IV Administration | ||||
| Subcutaneous Administration | ||||||
| Oral Formulation | ||||||
| Radiation Dermatitis | Severe side effect of radiation treatment in oncology - no treatments | IV Administration | ||||
| Sunburn | Huge market potential with no treatments available | Lotion | ||||